A carregar...
Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer
HER3/ErbB3 has emerged as a new therapeutic target for cancer. Currently, more than a dozen anti-HER3 antibodies are in clinical trials for treatment of various cancers. However, limited understanding of the complex HER3 signaling in cancer and lack of established biomarkers have made it challenging...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5323190/ https://ncbi.nlm.nih.gov/pubmed/27582551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11613 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|